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Catecholamines and cognition after traumatic
brain injury
Peter O. Jenkins,1 Mitul A. Mehta2 and David J. Sharp1
Cognitive problems are one of the main causes of ongoing disability after traumatic brain injury. The heterogeneity of the injuries
sustained and the variability of the resulting cognitive deﬁcits makes treating these problems difﬁcult. Identifying the underlying
pathology allows a targeted treatment approach aimed at cognitive enhancement. For example, damage to neuromodulatory
neurotransmitter systems is common after traumatic brain injury and is an important cause of cognitive impairment. Here, we
discuss the evidence implicating disruption of the catecholamines (dopamine and noradrenaline) and review the efﬁcacy of cate-
cholaminergic drugs in treating post-traumatic brain injury cognitive impairments. The response to these therapies is often variable,
a likely consequence of the heterogeneous patterns of injury as well as a non-linear relationship between catecholamine levels and
cognitive functions. This individual variability means that measuring the structure and function of a person’s catecholaminergic
systems is likely to allow more reﬁned therapy. Advanced structural and molecular imaging techniques offer the potential to
identify disruption to the catecholaminergic systems and to provide a direct measure of catecholamine levels. In addition, measures
of structural and functional connectivity can be used to identify common patterns of injury and to measure the functioning of brain
‘networks’ that are important for normal cognitive functioning. As the catecholamine systems modulate these cognitive networks,
these measures could potentially be used to stratify treatment selection and monitor response to treatment in a more sophisticated
manner.
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Introduction
In the developed world traumatic brain injury (TBI) is the
biggest cause of death and disability in the under-40 s
(Bruns and Hauser, 2003). Patients can be left with signiﬁ-
cant disabilities, requiring lifelong care with high social and
economic costs. Cognitive problems, including impairments
of attention, memory and executive functions, are a major
cause of this ongoing disability (Whitnall et al., 2006) and
are difﬁcult to treat effectively.
The heterogeneity of the injuries and the variability of the
resulting cognitive problems make their management
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particularly problematic. What is required are ways of
identifying common underlying pathologies that can guide
the use of treatment that enhances cognition. A promising
approach is to consider the effects of TBI on neuromodu-
latory transmitter systems. Dysfunction of these systems is
common after TBI and many potential therapeutic strate-
gies are available. Dopamine (Bales et al., 2009), noradren-
aline (Kobori et al., 2006), acetylcholine (Salmond et al.,
2005), and serotonin (Rosenthal et al., 1998) are impli-
cated in the pathogenesis of cognitive and neuropsychiatric
symptoms following TBI. In this review we focus on the
catecholamines (dopamine and noradrenaline).
The evidence implicating disruption to the catecholami-
nergic systems is mainly 3-fold: (i) they modulate the cog-
nitive functions commonly impaired following TBI; (ii)
disruption to these systems are seen following TBI; and
(iii) catecholaminergic drugs treat some cognitive deﬁcits
seen after TBI. Despite a clear rationale for treatment, the
effects of catecholaminergic medications are inconsistent
(Forsyth et al., 2006). This inconsistency is probably due
to the heterogeneity of traumatic injuries as well as the
non-linearity of the relationship between catecholaminergic
levels and cognitive function (Cools and D’Esposito, 2011).
This individual variability motivates a need to deﬁne the
state of a person’s catecholaminergic systems prior to
choosing treatment.
A number of neuroimaging approaches that quantify
catecholaminergic state and the response to treatment are
available. Molecular imaging techniques such as single
photon emission computed tomography (SPECT) and PET
directly measure the catecholamine systems (Egerton et al.,
2009; Lehto et al., 2015). Structural MRI can measure
damage to catecholaminergic nuclei, their efferent projec-
tions or the areas they project to. Functional MRI can
assess brain network dysfunction and response to treatment
(Husain and Mehta, 2011; Sharp et al., 2014). Here we
give a brief review of catecholaminergic anatomy, high-
lighting how it might be susceptible to damage following
TBI. We then review evidence that the catecholaminergic
systems are disrupted after TBI, discuss the cognitive def-
icits commonly seen after TBI and how the catecholamines
modulate them. We then highlight evidence for the use of
catecholaminergic treatments and ﬁnally discuss how
advanced neuroimaging techniques may be employed to
direct and monitor catecholaminergic treatments effectively.
Catecholaminergic anatomy
and physiology in the context
of traumatic brain injury
Dopamine and noradrenaline modulate brain function via
widespread ascending projections from their small brain-
stem nuclei (Fig. 1) (for detailed reviews see Beaulieu and
Gainetdinov, 2011; Haber, 2014; Chandler, 2015). These
nuclei, their ascending efferent pathways and their regula-
tory inputs are vulnerable to traumatic injury (Fig. 2).
Dopaminergic projections originate from a cluster of mid-
brain nuclei, predominantly the substantia nigra pars com-
pacta and the ventral tegmental area (Bjorklund and
Dunnett, 2007). Noradrenergic projections to the cerebral
cortex originate from the locus coeruleus in the pons
(Dahlstrom and Fuxe, 1964). The catecholaminergic nuclei
are therefore susceptible to brainstem injuries, which are
common following TBI, particularly in patients with poor
outcome (Adams et al., 1989) (Fig. 2A). This susceptibility
to injury may have a biomechanical explanation with com-
putational models of TBI predicting high strain across the
midbrain as a result of the brain pivoting in this region
(Zhang et al., 2001).
Catecholaminergic neurons may also be more susceptible
to disruption due to their physiological characteristics.
Dopaminergic neurons have a high baseline activity causing
elevated mitochondrial stress and increased vulnerability to
toxins (Lotharius et al., 1999; Surmeier et al., 2010a, b).
This maybe important early after injury when the brain is
under acute stress and may also make the cells vulnerable
to persistent effects seen after TBI, such as increased neu-
roinﬂammation (Fig. 2C) (Ramlackhansingh et al., 2011).
The catecholaminergic neurons project via ascending
pathways to subcortical and cortical target areas. In ex-
treme cases these axons may be severed (primary axotomy).
More commonly injury is produced through a biochemical
cascade leading to delayed cell death occurring over the
following hours to months (secondary axotomy)
(Maxwell et al., 1997). Catecholaminergic axons may be
particularly vulnerable to axonal injury. First, the length of
their ﬁbres and diffuse projection patterns expose them to
the differential shearing stresses (Fig. 2B). Second, the huge
size of their axonal arbour is associated with a high energy
cost for neural transmission, making them vulnerable to
metabolic stress (Pissadaki and Bolam, 2013) (Fig. 2D).
Third, catecholaminergic projections are poorly myelinated
or unmyelinated making them more susceptible to mechan-
ical injury (Reeves et al., 2005; Staal and Vickers, 2011).
Disruption to the afferent inputs to the catecholaminergic
systems may also occur following TBI. Dopaminergic nuclei
receive afferent input from the locus coeruleus and vice
versa. In addition, cortical regions such as the prefrontal
cortex (PFC) project into these nuclei (Arnsten and
Goldman-Rakic, 1984; Sara, 2009; El Mansari et al.,
2010). Hence, multifocal damage either within the brain-
stem or in widespread cortical or subcortical locations can
have a complex effect on the regulatory inputs of these
neuromodulatory systems.
The catecholaminergic systems have complex cellular
signalling mechanisms that can be disrupted following TBI
(Fig. 3). Dopamine is synthesized via the hydroxylation and
decarboxylation of L-tyrosine. In noradrenergic neurons,
dopamine beta-hydroxylase then catalyses the synthesis of
noradrenaline from dopamine (Grzanna and Molliver,
1980). Both are stored in vesicles for release at the
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presynaptic membrane. Once released, dopamine is inacti-
vated either via reuptake through the dopamine transporter
(DAT, encoded by SLC6A3) on dopaminergic neurons or
via uptake by glial cells (Meiser et al., 2013). It is then
either repackaged into vesicles for reuse or enzymatically
broken down by catechol-O-methyl transferase (COMT) or
monoamine oxidase. DAT is expressed exclusively on dopa-
minergic neurons. It is most highly concentrated in the sub-
stantia nigra, ventral tegmental area, striatum and nucleus
accumbens, and more sparsely in cortical regions (Ciliax
et al., 1999). Dopamine reuptake via DAT is the primary
mechanism controlling the lifetime of extracellular dopamine
Figure 1 Anatomy and firing patterns of the catecholaminergic systems. (A) Catecholaminergic efferent pathways and brainstem
nuclei. The dopaminergic system has three main efferent projections; the meso-striatal (green), meso-limbic and meso-cortical (both in red). The
meso-striatal projection supplies the striatum, the meso-limbic the limbic system including the nucleus accumbens and the meso-cortical pro-
jection supplies the majority of the cortex. The dopaminergic nuclei (the substantia nigra and ventral tegmental area) reside in the upper midbrain.
The main nucleus of the noradrenergic system is the locus coeruleus and is housed in the posterior pons. The locus coeruleus provides the sole
noradrenergic supply to most cortical regions. (B) Dopamine: (I) Tonic single spike activity in an inhibited dopaminergic neuron. (II) Bursting
activity in a dopaminergic neuron in response to a stimulus (electric foot shocks in an anaesthetized rat). Adapted with permission from Brischoux
et al. (2009). Noradrenaline: (I) Noradrenergic neurons in the locus coeruleus (LC) show increased firing rate depending on arousal level. Adapted
from Bouret and Sara (2010). (II) Sensory evoked field potentials in the locus coeruleus vary according to the arousal state (as measured via
electroencephalogram). Largest locus coeruleus field potential responses occur for stimuli experienced whilst the animal is awake as opposed to
during sleep. Adapted with permission from Aston-Jones and Bloom (1981b).
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in areas of high DAT expression (Gainetdinov et al., 1998).
In addition, DAT levels are regulated by dopamine itself via
interaction with the transporter and presynaptic autorecep-
tors (Williams and Galli, 2006). The noradrenaline trans-
porter primarily controls the reuptake of noradrenaline.
However, it also displays a high afﬁnity for dopamine.
Therefore, in areas of low DAT, such as the PFC, noradren-
aline transporter plays a prominent role in dopamine clear-
ance (Husain and Mehta, 2011). To support this,
noradrenaline transporter inhibitors increase both
noradrenaline and dopamine levels in the PFC without
affecting striatal dopamine levels (Carboni et al., 1990;
Bymaster et al., 2002). In addition to noradrenaline trans-
porter, COMT also plays a role in dopamine clearance
in the PFC. A common genetic variation in COMT,
which alters dopamine clearance rates, results in
differing levels of dopamine in the PFC (Tunbridge et al.,
2006).
The catecholaminergic systems have multiple receptors
with differing functions. Dopamine interacts with two
pharmacologically and physiologically distinct receptor
families, the D1-like (D1 and D5) and D2-like (D2, D3,
D4). See Table 1 for a summary and Beaulieu and
Gainetdinov (2011) for a detailed review. For noradren-
aline, three basic receptor subtypes have been classiﬁed,
-1, -2 and b receptors. These subtypes differ in terms
of binding afﬁnity, second messenger coupling and localiza-
tion (Table 1).
Both catecholaminergic neurons display tonic and phasic
discharge patterns, with distinct proposed roles (Fig. 1).
This is an important issue when considering treatment, as
systemic drug administration can modulate tonic levels but
cannot reproduce the phasic neuromodulation. In dopamin-
ergic neurons, phasic activity consists of a burst of neur-
onal discharges causing a rapid rise in intra-synaptic
dopamine levels. An efﬁcient reuptake system in the syn-
apse means that this increase is transient and does not raise
extracellular dopamine levels (Floresco et al., 2003). This
phasic activity has been extensively investigated and ap-
pears to code for motivational value and salience as well
as acting as an alerting signal to sensory cues (Bromberg-
Martin et al., 2010; Chang et al., 2016). In contrast, tonic
activity is characterized by regular, slow, continuous dis-
charges. The number of dopaminergic neurons ﬁring in this
pattern correlates closely with the concentration of extra-
synaptic dopamine levels and has been proposed to play a
more general role in preparing an organism to respond to
environmental cues (Grace, 1991; Floresco et al., 2003).
In noradrenergic neurons, tonic activity is related to the
animal’s behavioural state. During sleep and low arousal
states tonic activity is low. When the animal is awake and
alert there is moderate tonic ﬁring, rising to higher rates
during unregulated stress (Foote et al., 1980; Aston-Jones
et al., 1999). Extracellular levels of noradrenaline are lin-
early related to the tonic discharge rates of noradrenergic
neurons (Berridge and Abercrombie, 1999). Phasic activity
comprises a brief burst of two to three action potentials
followed by a prolonged period of suppression. It occurs
in response to behaviourally relevant stimuli and is most
strongly generated during moderate tonic activity, i.e. when
the animal is in an optimal state for task-focussed behav-
iour (Foote et al., 1980; Aston-Jones and Bloom, 1981b).
However, during stress or fatigue, phasic ﬁring becomes
less discriminatory and occurs in response to distractors
in addition to task-relevant stimuli (Aston-Jones et al.,
1999). Repeated stimulus presentation attenuates the
phasic ﬁring response with a resultant attenuation in the
behavioural response. In animals, this phasic response has
been closely associated with sustained attention in tests of
vigilance (Aston-Jones et al., 1994).
Figure 2 Potential mechanisms for catecholaminergic
disruption following TBI. (A) Haemorrhagic contusions in the
brainstem following TBI. The high shearing stresses present in this
region during trauma mean the catecholaminergic nuclei that reside
in the midbrain are susceptible to damage. (B) The long, tortuous
pathway of the efferent catecholaminergic axons throughout the
cerebrum exposes them to shearing forces at the time of injury. (C)
A 11C-(R)PK11195 (PK) PET image showing persistent microglial
activation following TBI (Ramlackhansingh et al., 2011), which may
causing persisting neuronal injury. (D) Reconstruction of a single
nigrostriatal dopaminergic axon showing the extensive arborization
of these neurons, which may make them vulnerable to metabolic
disturbances. Adapted with permission from Matsuda et al. (2009).
(E) Damage to the PFC following TBI may disrupt the ‘top-down’
control that PFC neurons exert over the dopaminergic and nora-
drenergic cells bodies in the brainstem.
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Evidence of catecholaminer-
gic disruption in traumatic
brain injury
Dopamine
TBI disrupts the dopamine system in animal models. Cell
loss occurs in the substantia nigra following cortical injury,
with a 25% reduction in dopaminergic neurons in the sub-
stantia nigra observed after 28 days in one model (van
Bregt et al., 2012). The loss is progressive, rising from
15% ipsilateral to injury at 11 days to 30% bilaterally at
26 weeks (Hutson et al., 2011), and is associated with
blood–brain barrier breakdown and microglial activation,
demonstrating an accompanying inﬂammatory process.
Dopamine levels have been shown to rise after TBI in
numerous regions throughout the brain including the brain-
stem, striatum, hypothalamus and medial prefrontal cortex
(Huger and Patrick, 1979; McIntosh et al., 1994; Massucci
et al., 2004; Kobori et al., 2006). However, these increases
are short-lived and followed by a hypodopaminergic func-
tional state (Wagner et al., 2005b). For example, dopamine
release, clearance and evoked overﬂow levels of dopamine
in the striatum are reduced 2 weeks after injury (Wagner
et al., 2005b). The reduced clearance in the context of
reduced dopamine release is likely to be a compensatory
mechanism aimed at maintaining extracellular dopamine
levels. In addition, tyrosine hydroxylase levels are normal
or raised following TBI (Wagner et al., 2005b; Yan et al.,
2007), providing a further potential compensatory mechan-
ism. The reduction in dopamine release in the context of
normal or increased synthesizing capacity implies a deﬁcit
in vesicular trafﬁcking, a reduction in the amount of dopa-
mine per vesicle, and/or an alteration of the usual auto
feedback control of dopamine release.
D1 and D2 receptor levels do not appear to be altered
chronically in animal models of TBI (Henry et al., 1997;
Wagner et al., 2005b, 2009a). In contrast, DAT expression
is reduced (Yan et al., 2002; Wagner et al., 2005a, b,
2009a; Wilson et al., 2005b; Shimada et al., 2014).
Striatal DAT expression is rapidly affected by dopamine
levels, neural activity and DAT inhibitors (Daws et al.,
Figure 3 Components of the catecholaminergic synapses. (A) Dopamine: The hexagons outline potential SPECT/PET ligand targets.
Example ligands are (1) 18F-fluoro-m-tyrosine or 11C-methyl-m-tyrosine; (2) 18F-DOPA or 11C-DOPA; (3) 11C-DTBZ; (4) 123I-Beta-CIT, 123I-FP-
CIT, 11C-cocaine; (5) 11C-SCH 23390, 11C-NNC 112; (6) 11C-PHNO, 11C-raclopride. (B) Noradrenaline: (1) 11C-MRB; (2) 11C-ORM-13070.
DOPA = L-3,4-dihydroxyphenylalanine; DA = dopamine; nvDA = non-vesicular dopamine; VMAT2 = vesicular monoamine transporter 2;
Gs = stimulative regulative G protein (stimulates adenylyl cyclase); Gi = inhibitory regulative G protein (inhibits adenylyl cyclase);
MAOB = monoamine oxidase B; TH = tyrosine hydroxylase; L-AAD = L-amino acid decarboxylase; DBH = dopamine beta-hydroxylase;
NET = noradrenaline transporter; Gq = G protein acting via phosphoinositol second messenger system; NorAd = noradrenaline;
nvNorAd = non-vesicular noradrenaline.
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2002; Gulley and Zahniser, 2003), making the changes
likely to be secondary to a loss of dopaminergic cells or
a compensatory downregulation of DAT due to reduced
dopamine levels. Evidence suggests the latter, as vesicular
monoamine transporter (VMAT), a measure of dopamine
cell density, is maintained. This is in contrast to dopamine
release and clearance, which is reduced (Vander Borght
et al., 1995; Kilbourn et al., 1996; Wagner et al., 2005b).
Surprisingly, there is relatively little work describing the
effects of TBI on the dopamine system in humans.
Neuropathological studies of subjects who suffered repeti-
tive head injuries show gross and microscopic changes to
the substantia nigra (see Smith et al., 2013 for a compre-
hensive review of the pathology). Although there are no
pathological studies identifying changes to this structure
following a single head injury, it seems plausible that they
are subject to similar pathological processes.
Two imaging studies in humans have demonstrated
altered DAT and D2 receptor binding in the striatum
through SPECT and PET imaging (Donnemiller et al.,
2000; Wagner et al., 2014). Donnemiller et al. (2000)
showed a reduction in DAT binding within the striatum
of over 50% via SPECT imaging using 123I-b-CIT in 10
patients who had suffered a severe TBI and were in a
persistent vegetative state or had persisting akinetic-rigid
features. Wagner et al. (2014) also demonstrated reduced
DAT levels in the striatum using the PET ligand 11C-b-
CFT; however, they found a smaller effect size of 20–30%
reduction in binding, variable injury severities were
thought likely to account for this discrepancy (Wagner
et al., 2014).
Donnemiller et al. (2000) also showed reduced D2 re-
ceptor binding using the SPECT tracer 123I-IBZM,
whereas Wagner et al. (2014) demonstrated higher D2
receptor binding within the ventral striatum using 11C-
raclopride. Wagner et al. (2014) argued that reduced
dopamine after TBI may lead to an increase in D2 recep-
tor binding due to reduced competitive binding with en-
dogenous dopamine and/or a compensatory upregulation
of D2 receptors. In the subregion where D2 receptor bind-
ing was increased (the ventral striatum), DAT levels were
not reduced. Therefore, there may be regional variation in
the compensatory downregulation of DAT to maintain
dopamine levels, hence causing variable dopamine levels
throughout the striatum. The increased injury severity of
the patients reported by Donnemiller et al. (2000) may
also have caused greater dopaminergic cell loss leading
to their ﬁndings of a reduction in both D2 receptors
and DAT.
Noradrenaline
There are fewer studies with less consistent ﬁndings for
the effects of TBI on the noradrenergic system. Animal
studies show inconsistent alterations in noradrenraline
levels after experimental TBI (McIntosh et al., 1994;
Prasad et al., 1994; Kobori et al., 2006). Studies ofT
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noradrenergic turnover provide the most consistent results,
with an acute increase over the ﬁrst 30min observed
around the site of injury (Levin et al., 1995; Dunn-
Meynell et al., 1998) followed by a reduction throughout
the brain over a subacute to chronic time scale (6 h to 8
weeks) (Dunn-Meynell et al., 1994, 1998; Fujinaka et al.,
2003). As adrenergic agents have been shown to improve
recovery and -1 receptor blockade to impede it in animal
models, this reduction in noradrenergic turnover in the
chronic phase may impair recovery (Boyeson and Feeney,
1990; Sutton and Feeney, 1992; Dunn-Meynell et al.,
1997).
Noradrenergic receptors have been less extensively stu-
died. Early work identiﬁed an acute reduction in binding
to -1 adrenoreceptors at the site of injury, progressing to a
more widespread reduction in -1 adrenoreceptor binding
from 24h to 30 days throughout the brain (Prasad et al.,
1992; Levin et al., 1994). More recently, however,
increased levels of -1 adrenoreceptor (ADRA1A) mRNA
have been detected in the medial PFC 14 days post-experi-
mental traumatic brain injury, suggesting a possible upre-
gulation (Kobori et al., 2011).
There is minimal work investigating alterations to the
noradrenergic system in humans. The locus coeruleus
shows neuronal cell loss following repetitive head injury
but, as with the substantia nigra, there are no pathological
studies examining the noradrenergic system following a
single injury (Smith et al., 2013). There have been no mo-
lecular imaging studies in humans.
The role of the catechola-
mines in cognitive functions
commonly affected by trau-
matic brain injury
Patients are often left with persistent cognitive impairments
after TBI that limit their recovery. Next we brieﬂy describe
the relationship between the catecholamines and these im-
pairments. We take this approach because it reﬂects current
clinical and neuropsychological practice. However, we ac-
knowledge that dividing cognitive deﬁcits into somewhat
arbitrary domains such as memory and attention can be
problematic and that patients often show complex patterns
of cognitive impairment that are not easily subdivided in
this way. Therefore, in the ﬁnal part of this section we
provide an example of how assessing disruption at a sys-
tem’s level, by measuring network function, may offer a
greater mechanistic insight. TBI produces disruption to
the neural networks associated with cognition and the cat-
echolamines have also been shown to modulate these net-
works. Therefore, this offers a potential tool by which
treatment can be targeted and response monitored.
The cognitive domains commonly affected are informa-
tion processing speed, attention, memory, learning and
executive functions (Levin and Kraus, 1994; Scheid et al.,
2006; Draper and Ponsford, 2008). A wide range of studies
show that catecholamines modulate these cognitive func-
tions, suggesting that drug treatments could be effective
after TBI. However, the relationship between catechol-
amine levels and speciﬁc cognitive functions is complicated.
Non-linear effects are seen and different neurotransmitter
systems interact with each other, producing a complex
mapping between neurotransmitter levels and cognitive
function (Cools and D’Esposito, 2011; Husain and
Mehta, 2011). While some discrimination between pro-
cesses modulated by neurotransmitter systems is possible
(e.g. dopamine and reinforcement learning), interactions be-
tween systems limit the degree to which selective agents for
dopamine and noradrenaline can be reliably aligned to spe-
ciﬁc deﬁcits (Husain and Mehta, 2011).
Information processing speed
Impairment of information processing speed is common
after TBI (Draper and Ponsford, 2008).
Catecholaminergic drugs can modulate processing speed
and conditions that reduce these neurotransmitters, such
as Parkinson’s disease, also affect processing speed. For
example, stimulant drugs that increase catecholamine
levels, including methylphenidate and D-amphetamine,
can improve speed of information processing (Halliday
et al., 1986, 1990). In addition, age differences in process-
ing speeds correlate with decreases in D2 receptor density
(Backman et al., 2000), and reaction times are speeded with
dopaminergic medications in patients with reductions in
dopamine secondary to Parkinson’s disease (Pullman
et al., 1988). Noradrenaline has also been shown to inﬂu-
ence processing speed. For example, clonidine, an -2 ad-
renergic agonist that reduces noradrenaline levels when
acting presynaptically, slows reaction times. In contrast,
yohimbine, an -2 adrenergic antagonist that increases nor-
adrenaline levels, improves reaction times (Halliday et al.,
1989).
Attention
Attention is often impaired after TBI. Deﬁcits include ori-
enting (Cremona-Meteyard et al., 1992), focusing (Chan,
2000; Bate et al., 2001), sustaining (Ponsford and
Kinsella, 1992) and dividing attention (Park et al., 1999).
Dopamine modulates attentional processes in a region-spe-
ciﬁc manner. In rats, reduced striatal dopamine impairs
response speed (Baunez and Robbins, 1999) and reduces
distractibility (Collins et al., 1998; Crofts et al., 2001).
Conversely, reduced PFC dopamine increases distractibility
and impairs sustained attention (Crofts et al., 2001).
Hence, these two brain systems appear to work synergis-
tically, with increases in PFC dopamine accompanied by
reciprocal decreases in the striatum and vice versa
(Pycock et al., 1980; Roberts et al., 1994; Kolachana
et al., 1995; Meyer-Lindenberg et al., 2005). One
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interpretation is that increased PFC dopamine stabilizes
neural activity relevant to current tasks and so reduces
distractibility, while increased striatal dopamine promotes
shifts in attention (Cools and D’Esposito, 2011). Taken to
the extreme, hypodopaminergia in the striatum would lead
to perseveration whereas a similar reduction in the PFC
would produce distractibility. Dopaminergic neurons are
also important in signalling salient sensory cues and
thereby orienting attention. Phasic release of dopamine
can signal both rewarded (Schultz, 1998; Chang et al.,
2016) and non-rewarding experiences (Bromberg-Martin
et al., 2010). These dopaminergic neurons project to the
dorso-lateral prefrontal cortex and dorsal striatum, and
may provide an alerting signal to help orient attention to
novel or important stimuli. Both increased distractibility
and perseveration are seen following TBI (Mathias and
Wheaton, 2007), which might reﬂect distinct dopaminergic
abnormalities in different patients.
Noradrenaline also modulates attention, with distinct
roles for tonic and phasic discharge patterns (Carli et al.,
1983; Cole and Robbins, 1992; Aston-Jones et al., 1999).
Tonic activity is related to arousal state (Foote et al., 1980).
Low activity levels are associated with reduced arousal and
disengagement from the environment (Aston-Jones and
Bloom, 1981a), moderate levels with focused task perform-
ance and appropriate ﬁltering of irrelevant stimuli (Usher
et al., 1999) and high levels with distractibility and
increased vigilance for irrelevant environmental events
(Valentino and Van Bockstaele, 2008). In contrast, locus
coeruleus neurons ﬁre phasically in response to novel sali-
ent stimuli or to changes in the signiﬁcance of a particular
stimulus (Sara and Segal, 1991; Aston-Jones et al., 1997;
Bouret and Sara, 2004). The close relationship between the
phasic activation of locus coeruleus neurons and stimulus-
induced attentional shifts has led to the proposal that nor-
adrenaline release from the locus coeruleus is also involved
in controlling shifts in attention (Bouret and Sara, 2005; Yu
and Dayan, 2005; Sara, 2009). In humans, pharmaco-
logical inhibition of cerebral noradrenaline release results
in impaired attention (Smith and Nutt, 1996), an effect
reversed by increased arousal, possibly mediated by
increased noradrenaline levels. Noradrenergic drugs have
also been used to enhance attentional impairment following
brain injury. For example, sustained attention can be im-
proved with the noradrenergic agonist guanfacine after
non-traumatic brain injury (Malhotra et al., 2006; Singh-
Curry et al., 2011).
Memory and learning
Memory and learning is frequently disrupted following TBI
(Draper and Ponsford, 2008). Animal studies show that
memory impairments can be produced by lesioning dopa-
minergic neurons in animal models (Gasbarri et al., 1996;
Schroder et al., 2003), an effect apparently caused by dis-
ruption to long-term potentiation in the hippocampi.
Dopamine release in the hippocampus is required to
promote protein synthesis that allows cellular consolidation
of these memories (Frey and Morris, 1997; O’Carroll et al.,
2006). In keeping with this mechanism, dopamine antag-
onists impair hippocampal-dependent memories after long
but not short delays (Bethus et al., 2010) and hippocampal
activation increases hippocampal dopamine release, thereby
facilitating memory encoding (Lisman et al., 2011). In
humans, levodopa enhances learning and memory forma-
tion in both healthy young (Knecht et al., 2004) and
healthy older subjects (Chowdhury et al., 2012). This
effect shows an inverted-U shaped dose-dependent re-
sponse, with both high and low doses proving ineffective
(Chowdhury et al., 2012). As in animal work, the effect of
dopamine is to improve delayed rather than early recollec-
tion performance.
Noradrenaline can enhance memory for emotionally
arousing events, especially in the context of stress
(Roozendaal et al., 2009). In humans, b receptor antagon-
ists block memory consolidation improvements generated
via emotional arousal (Schwabe et al., 2009).
Noradrenergic effects on the amygdala, hippocampus and
amygdala-hippocampal interactions appear to be particu-
larly important in strengthening these emotionally salient
memories (Ferry and McGaugh, 1999; Hatﬁeld and
McGaugh, 1999; Strange and Dolan, 2004; Yang and
Liang, 2014). Lesions in the amygdala impair the encoding
of emotionally salient events (Anderson and Phelps, 2001)
and functional imaging studies show increased amygdala
activity that is attenuated by b receptor antagonists when
Figure 4 Relationship between dopamine levels and per-
formance. There is an ‘inverted U-shaped’ relationship between
dopamine levels and cognitive performance with both too little and
too much dopamine causing impairment (red line). Different cog-
nitive tasks may, however, have different optimal levels (red and blue
lines representing two distinct cognitive tasks). Therefore an in-
crease in dopamine levels (represented by blue dashed horizontal
line) may impair one task (red line) while optimizing performance in
another (blue line). See also Arnsten et al. (2012) for a molecular
basis of this inverted U.
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subjects are presented with emotional stimuli (van Stegeren
et al., 2005). In addition, the noradrenergic system has
been shown to modulate interactions between the amygdala
and hippocampus in this context (Strange and Dolan,
2004). One interesting proposal is that the noradrenergic
system may play an important role in post-traumatic stress
disorder (Ramos and Arnsten, 2007). Over stimulation of
the noradrenergic system may enhance the memories of
stressful events via -1 and b receptor stimulation. To sup-
port this, -1 and b receptor antagonism can improve the
symptoms of post-traumatic stress disorder (Peskind et al.,
2003; Raskind et al., 2003; Vaiva et al., 2003).
Executive functions
Executive functions, such as working memory, planning,
and inhibitory control, are commonly affected by TBI
(Dikmen et al., 1995; Stuss and Alexander, 2007; Jilka
et al., 2014). Dopamine has been extensively investigated
with regards to its effects on executive functions, in par-
ticular working memory. Selective lesioning of the dopa-
minergic input to the PFC causes working memory
deﬁcits as profound as lesioning the entire PFC (Brozoski
et al., 1979). The D1 receptor is particularly important in
mediating these effects. Administration of D1 antagonists
causes selective impairments in working memory
(Sawaguchi and Goldman-Rakic, 1991; Arnsten et al.,
1994). An ‘inverted-U’ shaped relationship between dopa-
mine levels and working memory exists (Zahrt et al.,
1997), with either excessive inhibition or stimulation of
PFC D1 receptors causing impaired working memory
(Fig. 4). This implies the existence of an optimal level of
D1 receptor activation and has fundamental implications
for the effects of dopaminergic treatment on cognition
(Sawaguchi and Goldman-Rakic, 1991; Williams and
Goldman-Rakic, 1995; Zahrt et al., 1997).
This inverted-U shaped relationship is also evident in
humans. The response to dopaminergic stimulation is de-
pendent on baseline performance level, i.e. participants
with low baseline working memory capacity improve
with dopaminergic medications while those with high base-
line capacity are impaired (Kimberg et al., 1997; Gibbs and
D’Esposito, 2005). In addition, variations in the COMT
gene predict performance on working memory tasks. A
common functional single nucleotide polymorphism in the
COMT gene results in methionine (Met) replacing valine
(Val) and causes altered COMT activity. The Met allele
leads to reduced COMT activity and consequently
increased dopamine levels in the PFC (Cornish and
Wilding, 2010). Subjects with the Met allele perform
better on working memory tasks (Meyer-Lindenberg
et al., 2005). Furthermore, overall variation in working
memory performance ﬁts an inverted-U shaped function
with those with lower and higher predicted dopamine
levels performing worse (Fallon et al., 2015). Low working
memory is also associated with reduced dopamine synthesis
capacity measured by FMT PET, which predicts the
cognitive response to administration of a dopamine agonist
(Cools et al., 2008, 2009).
Dopaminergic medications improve executive functions
in diseases affecting dopamine levels e.g. Parkinson’s dis-
ease (Lees and Smith, 1983). Cognitive deﬁcits are generally
improved by treatment with levodopa or other dopamin-
ergic medication (Cooper et al., 1992) and are exacerbated
by medication withdrawal (Lange et al., 1992). However,
dopaminergic medication can impair other functions. For
example, following dopaminergic medication withdrawal
feedback-based learning improves (Fern-Pollak et al.,
2004; Cools, 2006). These differential effects of treatment
withdrawal, with impaired working memory and executive
functions, but improved feedback-based learning, involve
different striatal circuits. Working memory impairments
in the hypodopaminergic state are thought to be mediated
by fronto-striatal circuits passing through the dorsal stri-
atum (Mattay et al., 2002; Ekman et al., 2012). The ventral
portion of the striatum mediates the feedback-based learn-
ing effects (Cools et al., 2007). The ventral portion of the
striatum is vulnerable to ‘overdosing’ with dopamine medi-
cation as it is relatively spared of dopaminergic deﬁcit in
the early stages of Parkinson’s disease, but may be similarly
vulnerable in healthy volunteers (Mehta et al., 2001).
Therefore, different inverted-U shaped functions may be
present within different brain circuits and differentially
affect different tasks mediated by these circuits (Fig. 4).
Noradrenaline modulates executive functions via its -2A
receptor (Arnsten and Li, 2005). Like dopamine, animal
studies show impairment of working memory with deple-
tion of noradrenaline in the PFC (Arnsten and Goldman-
Rakic, 1985). Stimulation of -2A receptors either system-
ically (Arnsten and Contant, 1992; O’Neill et al., 2000) or
locally within the PFC leads to improvements in working
memory (Arnsten and Goldman-Rakic, 1985; Cai et al.,
1993; Mao et al., 1999; Ramos et al., 2006). There is
some evidence that dopaminergic and noradrenergic sys-
tems improve working memory via complimentary but dis-
tinct mechanisms. For example, during a working memory
task -2A stimulation increases delay period ﬁring in the
preferred direction of the neuron i.e. it strengthens the
signal (Wang et al., 2007), whereas D1 stimulation de-
creases ﬁring in the non-preferred direction of the neuron
i.e. it reduces noise (Vijayraghavan et al., 2007).
Noradrenaline also shows an inverted-U relationship with
working memory function. However, unlike dopamine, im-
paired performance at higher concentrations is not caused
by overstimulation of the -2A receptor (as with the D1
receptor) but rather by stimulation of the lower afﬁnity -1
and b receptors (Arnsten and Jentsch, 1997; Arnsten et al.,
1999, 2012; Mao et al., 1999).
In humans, reduced noradrenaline synthesis due to a
polymorphism in the dopamine beta hydroxylase enzyme
leads to impaired executive functioning and impulse control
(Kieling et al., 2008; Hess et al., 2009) and the -2A agon-
ist guanfacine improves working memory and planning in
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healthy young adults (Jakala et al., 1999), although this
latter ﬁnding has not been replicated (Muller et al., 2005).
Network dysfunction and catechola-
mine actions
Catecholaminergic effects on the brain and treatment re-
sponses can also be described at the level of systems neuro-
science. Cognitive functions frequently affected by TBI such
as memory and attention depend on the coordinated action
of widespread, non-adjacent brain regions (Mesulam,
1998). These distinct brain regions are connected via the
white matter tracts into large-scale networks, so-called in-
trinsic connectivity networks (ICNs) (Seeley et al., 2007).
TBI commonly produces white matter damage (Strich,
1956), thereby impairing the structural connectivity be-
tween brain regions, which in turn impairs the functional
interaction between network nodes and hence disrupts ICN
function (Sharp et al., 2014). Disruption to ICN function
following TBI has been frequently demonstrated, with the
degree of disruption predicting the level of cognitive im-
pairment (Bonnelle et al., 2011, 2012; Hillary et al.,
2011; Stevens et al., 2012; Zhou et al., 2012). In addition,
the impact of drug treatment in other contexts on the func-
tioning of these large-scale neural networks that underpin
higher-level cognitive processes can also be informative
(Husain and Mehta, 2011). Neuropsychological constructs
often do not map neatly onto the functioning of these ICNs
(Hampshire and Sharp, 2015). Therefore, it is likely to be
informative to consider both network dysfunction after TBI
and catecholaminergic treatment effects at the level of
large-scale network function.
This network approach can be illustrated by considering
abnormalities within speciﬁc ICNs, e.g. the default mode
network (DMN) and salience/cingulo-opercular network
(SN/CoN). TBI patients often show a failure to control
DMN activity, with high levels of activity in the central
node of the DMN (the posterior cingulate cortex) asso-
ciated with slower information processing (Sharp et al.,
2011) and abnormalities in functional connectivity within
the network associated with impaired sustained attention
(Bonnelle et al., 2011). These functional abnormalities are
related to abnormal structural connections within the
DMN (Bonnelle et al., 2011) and altered interactions be-
tween the SN/CoN and the DMN (Leech and Sharp, 2014).
Anti-correlated neural activity is normally observed be-
tween the DMN and a large fronto-parietal network
involved in supporting task performance when attention
is directed externally, the fronto-parietal control network
(Kelly et al., 2008). If attention is externally focused then
activity within the fronto-parietal control network increases
and a load-dependent decrease in DMN activity is observed
(Singh and Fawcett, 2008). A loss of this tightly controlled
anti-correlation is seen in a number of disease states (Leech
and Sharp, 2014). After TBI this abnormal network inter-
action reﬂects abnormalities in the connections of the SN/
CoN, which appear to disrupt this network’s role in switch-
ing the focus of attention in reponse to salient environmen-
tal events (Bonnelle et al., 2012; Jilka et al., 2014; Uddin,
2015).
The functioning of these networks is inﬂuenced by the
catecholamines, which appear to play an important role
in regulating their activity levels and interactions.
Therefore, speciﬁc network abnormalities might be targeted
for treatment with particular catecholaminergic drugs. The
level of dopamine synthesis capacity, measured via PET
imaging with the tracer 6-18F-ﬂuoro-L-m-tyrosine, correl-
ates positively with enhanced coupling between nodes of
the SN/CoN and the DMN and reduced coupling between
the SN/CoN and fronto-parietal control network at rest
(Dang et al., 2012). This modulation of internetwork cou-
pling supports a role for dopamine in tuning cognitive con-
trol by regulating the interaction of these ICNs, which, as
detailed above, can be impaired after TBI (Jilka et al.,
2014).
Pharmacological manipulation of these network inter-
actions has also been shown with catecholaminergic medi-
cations. For example, dopamine release, induced with
dextroamphetamine and measured with 123I-IBZM
SPECT, reduces connectivity within the DMN and SN/
CoN and is positively associated with connectivity changes
within a predeﬁned cortico-striatal-thalamic network
(Schrantee et al., 2015). Also, levodopa administration
has been shown to alter the connectivity between subcor-
tical and cortical regions in healthy adults (Cole et al.,
2013b). In addition, both linear and non-linear (i.e. in-
verted ‘U’) dopaminergic effects of pharmacological ma-
nipulation on connectivity patterns have been observed
with levodopa and haloperidol (Cole et al., 2013a), sug-
gesting that network responses reﬂect the complex relation-
ship of catecholamines to behaviour. The cognitive
enhancement produced by methylphenidate is accompanied
by changes in DMN activity (Marquand et al., 2011;
Tomasi et al., 2011). Changes in striatal dopamine have
been proposed to have a key regulatory role on the func-
tioning of the posterior cingulate cortex (Kelly et al., 2009;
Sambataro et al., 2013) and cognitive enhancement pro-
duced by methylphenidate is accompanied by decreased ac-
tivation within the posterior cingulate cortex/DMN activity
(Marquand et al., 2011; Tomasi et al., 2011). Given the
relationship between post-TBI cognitive difﬁculties and
increased activation within the posterior cingulate cortex,
this last ﬁnding provides a systems level explanation of
how methylphenidate may act as a cognitive enhancer
after TBI and may provide a method for predicting and
measuring response to treatment.
For noradrenaline, upregulation of the noradrenergic
system using clonidine (an -2 adrenoreceptor agonist) in
healthy human subjects performing an attentional task
causes an increase in the functional connectivity on PET
imaging within the fronto-parietal control network and
also between the locus coeruleus and nodes of the fronto-
parietal control network (Coull et al., 1999). Conversely,
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the administration of a noradrenergic antagonist reduces
the connectivity within the SN/CoN (Hermans et al.,
2011). These ﬁndings imply a role for noradrenaline in
modulating the neural networks involved in attentional
processes and more speciﬁcally demonstrate its effects on
the SN/CoN, disruption of which is associated with atten-
tional difﬁculties following TBI (Bonnelle et al., 2012).
Catecholaminergic therapies
Several catecholaminergic medications have been used to
treat cognitive problems following TBI with varying de-
grees of success. Methylphenidate and amantadine have
the most evidence for efﬁcacy (Tables 2 and 3), with less
available for dextroamphetamine, bromocriptine, atomox-
etine, guanfacine and levodopa (Supplementary Tables
1–5). The majority of trials have focused on using these
medications as short-term cognitive enhancers, with assess-
ment after a single dose or a short course of treatment.
However, catecholamines may also have an effect on neu-
roplasticity, shown for example by their role in modulating
hippocampal long-term potentiation (Frey and Morris,
1997; O’Carroll et al., 2006; Kabitzke et al., 2011;
Morris and Gold, 2012). Persistent effects once treatment
has ﬁnished have been less frequently studied (Kaelin et al.,
1996; Plenger et al., 1996; Pavlovskaya et al., 2007).
Methylphenidate
Mode of action
Methylphenidate is a psychomotor stimulant. Its primary
mechanism of action is blockade of the noradrenaline and
dopamine transporters (Solanto, 1998), but it also increases
dopamine release via D2 receptor-dependent modulation of
vesicular trafﬁcking (Volz et al., 2007, 2008). These mech-
anisms increase extracellular levels of both noradrenaline
and dopamine, which is believed to be the primary mech-
anism by which methylphenidate improves cognition
(Berridge et al., 2006). In animal models of TBI, methyl-
phenidate improves working memory and attention via
stimulation of both D1 dopamine receptors and -2 adre-
noreceptors in the PFC (Arnsten and Dudley, 2005).
There is also evidence that methylphenidate might in-
crease neuroplasticity and so promote longer-term cognitive
improvements. In animal models, single doses of methyl-
phenidate do not augment either basal or evoked extracel-
lular dopamine levels (Wagner et al., 2009b). However, 2
weeks of daily pretreatment leads to increased dopamine
levels in response to the drug, implying that methylphenid-
ate may be inducing functional changes in DAT or changes
in DAT trafﬁcking. Methylphenidate has also been shown
to amplify long-term potentiation in the hippocampus
(Rozas et al., 2015), an effect modulated via activation of
b adrenergic and D1/D5 receptors.
Evidence of use
In humans, 17 studies to date have assessed methylphenid-
ate’s effect on cognition following TBI (Table 2). These
studies differ greatly in design, time after injury and contain
relatively few patients (range 1–44, mean 20). The majority
assess the response to methylphenidate over 1–6 weeks
with two studies assessing response after a single dose
(Kim et al., 2006, 2012). Three trials assessed whether a
residual effect remained after stopping the medication
(Kaelin et al., 1996; Plenger et al., 1996; Pavlovskaya
et al., 2007). In these studies, cognitive testing was repeated
at 1, 3, or 8 weeks following treatment cessation, with
persisting improvements seen in the studies reassessing at
1 and 3 weeks (Kaelin et al., 1996; Pavlovskaya et al.,
2007) but not in the study that reassessed at 8 weeks
(Plenger et al., 1996).
The majority of trials (n = 9) show improvements in in-
formation processing speed (Evans et al., 1987; Kaelin
et al., 1996; Whyte et al., 1997, 2004; Al-Adawi et al.,
2005; Kim et al., 2006, 2012; Willmott and Ponsford,
2009; Willmott et al., 2013; Johansson et al., 2015) with
one trial showing persisting improvement a week after drug
cessation (Kaelin et al., 1996). These improvements in
speed did not come at the expense of accuracy (Whyte
et al., 2004; Willmott and Ponsford, 2009; Kim et al.,
2012).
The effect of methylphenidate on attention is less clear.
One detailed trial evaluated the effect of methylphenidate
on a range of attentional measures including standard cog-
nitive tests, observed attentiveness, productivity and care-
giver assessments (Whyte et al., 2004). Participants were
noted to be more attentive whilst performing tasks and
caregiver ratings of attention were also signiﬁcantly raised
on treatment, suggesting functionally signiﬁcant real-world
beneﬁts. Several other trials also show an improvement in
attention (Evans et al., 1987; Gualtieri and Evans, 1988;
Plenger et al., 1996; Al-Adawi et al., 2005; Lee et al., 2005;
Kim et al., 2006, 2012; Pavlovskaya et al., 2007) but
almost an equal number of studies failed to ﬁnd a beneﬁt
(Mooney and Haas, 1993; Speech et al., 1993; Whyte
et al., 1997; Tiberti et al., 1998; Willmott and Ponsford,
2009).
There is limited evidence that methylphenidate improves
memory functions. Three trials demonstrated improvements
in some memory tests (Evans et al., 1987; Gualtieri and
Evans, 1988; Kaelin et al., 1996), but the majority of
trials failed to show a signiﬁcant improvement (Mooney
and Haas, 1993; Speech et al., 1993; Plenger et al., 1996;
Tiberti et al., 1998; Willmott and Ponsford, 2009; Kim
et al., 2012). Executive functions, including working
memory, also fail to show a consistent improvement
across studies. Two studies showed a beneﬁt in certain ex-
ecutive functions, with one showing persistent beneﬁt 1
week later (Kaelin et al., 1996; Kim et al., 2006). Other
studies have failed to show improvements in working
memory (Willmott and Ponsford, 2009; Kim et al., 2012).
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Two studies assessed impact on functional outcomes. A
randomized, controlled study (Plenger et al., 1996) showed
a signiﬁcant improvement in functional outcome after 4
weeks of treatment but this effect was no longer apparent
2 months after stopping medication. These results imply
methylphenidate may accelerate the recovery process but
its effect on longer-term outcomes is unclear.
Amantadine
Mode of action
Amantadine has a mixed set of actions including weak an-
tagonism at the N-methyl D-aspartate (NMDA) receptor.
NMDA receptors are distributed throughout the striatum
with a presence on presynaptic dopamine terminals and
GABA interneurons. Blockade of the former causes reduc-
tions in dopamine release and thus the latter mechanism is
more likely to be important for the actions of amantadine
on dopamine release. The GABAergic interneurons are
located postsynaptically to the dopamine terminals in the
striatum. Glutamate signalling through the NMDA recep-
tors inhibits dopamine release via local regulation and
through modulation of inputs from the ventral pallidum
and cortical inputs (Kegeles et al., 2000; Hernandez
et al., 2003). Excitatory cortical inputs into the striatum
can also disinhibit striatal GABAergic interneurons
(Farber et al., 2003; Homayoun and Moghaddam, 2007),
and this may contribute to the enhancing effects of aman-
tadine on dopamine release.
Evidence of use
Six studies of mixed design suggest potential improvement of
cognitive problems post TBI with amantadine (Table 3). The
largest study randomized 184 vegetative or minimally con-
scious TBI patients into either an amantadine or placebo
group 4–16 weeks after injury (Giacino et al., 2012). This
study showed accelerated recovery in behaviour over the 4
weeks of treatment, although this effect was lost 2 weeks
after drug cessation. It is therefore not clear from this study
whether amantadine improves long-term outcome or accel-
erates the recovery process to a similar end-point. An earlier
smaller study also showed accelerated recovery in the acute
setting (Meythaler et al., 2002). One case series, one case
study and a retrospective chart review all showed improve-
ments in measures of attention, information processing speed
and executive functions when amantadine was given in the
chronic phase (Nickels et al., 1994; Kraus and Maki,
1997a,b). The case study showed an additional beneﬁt
when levodopa was given in combination with amantadine
(Kraus and Maki, 1997a). However, another small (n = 10)
double-blind, randomized, controlled trial failed to show any
signiﬁcant effects (Schneider et al., 1999). An interesting
open-label designed study showed improvements in execu-
tive functions that correlated with increased left PFC resting
metabolism identiﬁed by 18F-FDG PET (Kraus et al., 2005),T
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providing a possible mechanistic insight into the drug’s
mode of action.
Dextroamphetamine
Mode of action
Dextroamphetamine increases catecholamine levels by in-
hibiting presynaptic reuptake via downregulation of cate-
cholaminergic transporter expression (Kahlig and Galli,
2003), stimulating catecholaminergic release and inhibit-
ing monoamine oxidase (Fleckenstein et al., 2007).
Evidence of use
Two single case controlled studies and one retrospective
observational study have assessed the use of dextroam-
phetamine post-TBI (Supplementary Table 1). The retro-
spective study identiﬁed 9 of 15 patients who responded
to treatment but signiﬁcant experimental ﬂaws make in-
terpretation of this result difﬁcult (Hornstein et al.,
1996). Two studies used a double-blind, crossover
design in a single patient. Both demonstrated improve-
ments in information processing speed and sustained at-
tention, with one also showing improvements in verbal
learning (Evans et al., 1987; Bleiberg et al., 1993).
Bromocriptine
Mode of action
Bromocriptine is a selective D2 dopamine receptor agon-
ist, binding to both presynaptic autoreceptors (which in-
hibit dopamine release) as well as postsynaptic sites (Fuxe
et al., 1981). Due to its higher afﬁnity for the presynaptic
autoreceptor, it has been proposed to have an inhibitory
effect on dopamine function at lower doses, whereas at
higher doses its effects at the postsynaptic receptor are
thought to predominate, resulting in a facilitatory effect
on the dopaminergic system (Meltzer et al., 1983;
Luciana and Collins, 1997).
However, one study suggested that low doses in ro-
dents (2.5 and 5mg/kg) could increase extracellular dopa-
mine levels (Brannan et al., 1993), aligning with in vitro
evidence that at low concentrations bromocriptine can
act as a partial D2 antagonist (Lieberman and
Goldstein, 1985). The relevance of this potential increase
in dopamine levels after single, low doses to the use of
the drug in clinical settings is not currently known.
Therefore, bromocriptine has a complex effect on the
dopaminergic system that is dependent on the dose,
mediated through a combination of pre- and postsynaptic
effects.
Evidence of use
There is mixed data regarding the use of bromocriptine
(Supplementary Table 2). One case series identiﬁed an
improvement in all cognitive outcomes measured
(working memory, list learning and verbal ﬂuency), anT
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effect that persisted for 2 weeks following drug cessation
(Powell et al., 1996). A further randomized, controlled trial
showed a single low dose (2.5mg) improved certain execu-
tive functions (e.g. planning and inhibition). Other cogni-
tive functions such as working memory did not improve,
leading the authors to conclude that bromocriptine had a
targeted effect on these cognitive processes rather than a
non-speciﬁc improvement in arousal or attention
(McDowell et al., 1998). A retrospective case review also
showed a greater degree of functional recovery when used
in severe cases over a 2–6 month window (Passler and
Riggs, 2001). More recent randomized trials, however,
using both regular higher dosing (5mg twice daily for 6
weeks) and a single low dose (1.25mg) failed to show a
beneﬁt in attention or working memory (Whyte et al.,
2008; McAllister et al., 2011a).
Atomoxetine
Mode of action
Atomoxetine increases extracellular levels of noradrenaline
via inhibition of noradrenaline reuptake. It has high afﬁnity
for the noradrenaline transporter and much lower afﬁnity
for DAT (Bymaster et al., 2002). Animal models, however,
have shown that in the PFC it increases dopamine levels as
well as noradrenaline (Bymaster et al., 2002; Swanson
et al., 2006), which is likely to be due to the role of the
noradrenaline transporter in regulating dopamine levels in
the PFC (Bari and Aston-Jones, 2013). There is also evi-
dence that atomoxetine acts as an NMDA antagonist at
clinically relevant doses (Ludolph et al., 2010).
Evidence of use
Just one trial has explored the use of atomoxetine. Fifty-
one patients with a moderate-to-severe traumatic brain
injury and self-reported attentional problems did not
show improvement over a 2-week treatment period
(Ripley et al., 2014).
Guanfacine
Mode of action
Guanfacine is a selective -2A noradrenergic agonist.
Alpha-2A receptors are predominantly concentrated in the
PFC and the locus coeruleus and have been widely impli-
cated in the control of PFC cognitive functions (Arnsten,
1998).
Evidence of use
One trial including functional MRI showed a beneﬁt in
working memory in 13 patients with mild traumatic brain
injury 1-month post-injury (McAllister et al., 2011b). The
functional imaging showed increased activation in working
memory associated regions, suggesting its effects maybe via
direct manipulation of PFC functioning. Interestingly, this
group tested the same working memory paradigm with
bromocriptine and found no beneﬁt (McAllister et al.,
2011a). Therefore, given the evidence that both methylphen-
idate (a dual dopaminergic and noradrenergic agonist) and
guanfacine (a selective -2A noradrenergic agonist) improve
working memory but bromocriptine (a dopamine D2 recep-
tor agonist) does not, the results suggest that noradrenergic
-2A receptor stimulation, or stimulation of dopamine D1
receptors as these can have similar downstream intracellular
effects (Arnsten et al., 2012), maybe key to improving work-
ing memory function.
Levodopa
Mode of action
Levodopa is the precursor to dopamine. It is converted
within dopaminergic neurons to dopamine via the enzyme
L-amino acid decarboxylase (L-AAD).
Evidence of use
There has been one small observational study (Lal et al.,
1988). Twelve moderate-to-severe patients were assessed on
a titrated dose of levodopa (combined with carbidopa) with-
out placebo control. The study suggested improvements
based on clinical observation in a range of cognitive domains
but a formal, properly controlled study is clearly required.
Stratifying patient treatment
based on catecholaminergic
function
Although there is a broad evidence base that catecholami-
nergic medications can improve certain cognitive impair-
ments following TBI, the magnitude of effects in
individual patients are very variable. This variability reﬂects
the heterogeneous nature of TBI and has important impli-
cations for future work. Clinical trials in unselected TBI
patients need large numbers to be adequately powered,
and to date many have been underpowered (Warden
et al., 2006). One way to improve the design of future
trials is to select patient subgroups based on the presence
of speciﬁc types of neuropathology that are more likely to
respond to speciﬁc cognitive enhancers. An individual’s
‘catecholaminergic status’ is likely to be a key factor deter-
mining catecholaminergic treatment response because the
synaptic concentrations of catecholamines are non-linearly
related to cognitive function (the inverted-U relationship
discussed above). A principled way to select patients for
trials would be to deﬁne an individual’s catecholaminergic
state after TBI. Advanced imaging techniques using struc-
tural, molecular and functional imaging techniques all offer
the potential to directly assess the catecholaminergic sys-
tems and therefore help guide treatment selection (Fig. 5).
In addition, innate factors such as age, gender and genetics
that alter an individual’s catecholaminergic status might be
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incorporated into these decisions as they inﬂuence a pa-
tients ‘position’ on the inverted-U curve.
Structural imaging
Structural imaging techniques allow damage to the catecho-
laminergic systems to be assessed. Damage to the brainstem
nuclei can be assessed visually using standard MRI se-
quences. For example, susceptibility weighted imaging pro-
vides a sensitive marker for microhaemorrhages. More
sophisticated quantitative approaches provide additional in-
formation. Volumetric measures can quantify atrophy
within brainstem nuclei [Fig. 5A(III)]. In addition,
damage to the structural connections can be measured
using diffusion imaging. Although the catecholaminergic
ﬁbres are poorly myelinated and therefore unlikely to be
directly measured by techniques such as diffusion tensor
imaging (DTI), the white matter tracts through which
they travel could be used as a surrogate marker for
damage to the ascending catecholaminergic ﬁbres. In
Parkinson’s disease, DTI techniques have been used to
assess the integrity of the ‘nigrostriatal tract’ and show
abnormalities consistent with the degree of motor deﬁcits
in these patients (Zhang et al., 2015). A similar approach
could be used in TBI patients [Fig. 5A(II)], with the result-
ing measures potentially used as the basis for machine
learning methods to predict effects of TBI in individuals
(Hellyer et al., 2013).
Molecular imaging
Molecular imaging allows direct measurement of catecho-
laminergic function. Numerous PET and SPECT ligands are
available to measure dopamine function and others are in
development for the noradrenergic system (Ding, 2014; Fig.
3). The dopaminergic ligands available can be used to
assess synthesis capacity, receptor density as well as dy-
namic endogenous release of dopamine (Farde et al.,
1987; Volkow et al., 1994; Cumming et al., 1997). These
have been applied widely in Parkinson’s disease and other
neurodegenerative conditions (Tai and Pavese, 2013), but
have been used surprisingly little in TBI.
As already discussed, two studies show dopaminergic
abnormalities following TBI, including reductions in striatal
DAT levels using both SPECT (Donnemiller et al., 2000)
and PET (Wagner et al., 2014). SPECT imaging offers the
advantages of lower cost and commercial availability, with
ligands such as 123I-ioﬂupane (DaTScan) already widely
used clinically to aid the diagnosis of parkinsonian dis-
orders. PET, however, provides greater spatial resolution
and improved quantitative assessment. One important con-
sideration to bear in mind when performing molecular ima-
ging is the effect of atrophy or focal tissue loss, which are
both common following TBI, this reduces apparent ligand
binding potential and therefore needs to be accounted for
when using these techniques.
In both normal ageing and Parkinson’s disease, reduced
striatal DAT levels have been shown to relate to cognitive
deﬁcits (Marie et al., 1999; Muller et al., 2000; Mozley
et al., 2001). However, it is currently unclear how striatal
DAT levels relate to cognitive function after TBI and
whether they predict treatment response. Two of the au-
thors (P.O.J. and D.J.S.) are currently conducting a clinical
trial of methylphenidate where we will test whether striatal
DAT levels predict treatment response (Imperial College
London, 2016).
Further molecular imaging studies are needed to explore
the exact nature of catecholamine disruption in TBI pa-
tients and its relation to cognitive function. 18F-
DOPA can be used to assess dopamine synthesis in the
presynaptic terminal (Cumming et al., 1997). In
Parkinson’s disease, reductions in this tracer in the caudate
correlate with impairments in neuropsychological perform-
ance (Bruck et al., 2001). Behavioural abnormalities after
TBI may be mediated through distinct catecholaminergic
receptors and these could be probed using molecular ima-
ging. D1 receptors are related to many aspects of cognitive
function affected by TBI and their levels can be measured
using 11C-SCH 23390 and 11C-NNC 112 (Elsinga et al.,
2006). In addition, extrastriatal D2/3 receptors can be mea-
sured with 11C-PHNO, which may have relevance in
neuropsychiatric problems following TBI (Wilson et al.,
2005a).
Animal work demonstrates a dynamic element to dopa-
mine abnormalities after TBI, with reduced dopamine re-
lease from intact dopaminergic terminals (Wagner et al.,
2005). This ﬁnding suggests that dynamic measures of cat-
echolamine function may be necessary to fully characterize
abnormalities after TBI. PET provides methods to
study this. For example, 11C-raclopride is a displaceable
D2/3 receptor antagonist (Farde et al., 1986) that can pro-
vide quantitative information about striatal D2/3 receptor
levels, but is also sensitive to ﬂuctuations in endogenous
dopamine release as increasing dopamine levels reduce
11C-raclopride binding due to competitive binding (Breier
et al., 1997; Laruelle, 2000). This latter property allows ‘dy-
namic’ assessment of an individual’s dopaminergic system
in response to either medication (such as a stimulant) or
increased cognitive demands (Egerton et al., 2009).
The noradrenergic system has been less extensively
investigated via nuclear imaging methods, although sev-
eral noradrenaline transporter (NET) ligands have been
developed and are increasingly being used in research
(Ding, 2014). More recently, an -2C adrenoreceptor
ligand (11C-ORM-13070) has been shown to be sensitive
to monitoring extracellular noradrenaline concentrations,
thereby offering the potential to assess noradrenergic
neurotransmission in vivo (Lehto et al., 2015). As nor-
adrenaline abnormalities are likely to be central to some
cognitive impairments after TBI, the application of speciﬁc
noradrenergic ligands in TBI is a promising research
direction.
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Network function
As discussed above, measuring activity within ICNs such as
the DMN provides another potential method of guiding
treatment choices. Network abnormalities after TBI can
be identiﬁed using techniques such as functional MRI,
which could allow a more rational choice about drug treat-
ment as information accumulates about the network effects
Figure 5 Assessment of the catecholaminergic systems. (A) Structural assessment. (I) Standard MRI sequences can be used to assess
evidence of damage to catecholaminergic structures (e.g. the brainstem nuclei). Susceptibility weighted imaging (SWI), T1 and fluid-attenuated
inversion recovery (FLAIR) sequences are differentially sensitive. This example shows these three sequences in the same individual with no
obvious damage on T1 or FLAIR but evidence of small haemorrhages in the upper mid-brain/cerebral peduncles on susceptibility weighted imaging.
(II) White matter damage is common after TBI and can be assessed using MRI techniques such as DTI. Whole brain analysis can be performed in
an individual with the top left image demonstrating areas with increased damage (red) compared to a normative control group. By specifying a
region of interest (e.g. white matter area containing the nigrostriatal tract highlighted in purple in the top right image), damage to specific tracts can
be assessed. (III) Volumetric analysis of the substantia nigra. (B) Molecular assessment. (I) 123I-Ioflupane (DaTscan) and PHNO. (II) 11C-(S,S)-
methylreboxetine (11C-MRB) ligand that binds to the noradrenaline transporter (Smith et al., 2015). (C) Functional connectivity and ICN
assessment. (I) Functional connectivity analyses can be used to assess impairments in functional connectivity between different regions of interest.
This may provide a biomarker for damage to the catecholaminergic systems, e.g. disruption in the functional connectivity between the brainstem
(blue) and cortical regions (nodes in the default mode network in red/yellow). (II) Connectivity within and between ICNs for an individual can
provide a unique signature that may provide information regarding injury and relate to the cognitive deficits. Assessment of a derived connectivity
matrix has the potential to be used to guide treatment as well as assessing an individual’s response to treatment. FPCN = fronto-parietal control
network.
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of particular drugs. For example, if methylphenidate is
known to enhance the normal task-dependent deactivation
of the DMN that is lost after TBI, then the drug would be a
logical choice in patients with this network abnormality.
Therefore, assessing an individual’s impairments in network
activity using functional MRI offers a potential mechanism
by which treatment may be selected if the effect of the
treatment at this network level is known (Fig. 5C) (Leech
and Sharp, 2014). In addition, this approach allows treat-
ment response to be measured. This network-based ap-
proach could be particularly useful following TBI, where
patients have a wide-range of underlying causes for cogni-
tive problems that will require distinct approaches to
treatment.
Innate and genetic factors affecting
catecholaminergic status
Many innate factors also affect the catecholaminergic sys-
tems and are likely to inﬂuence the choice of treatment
following TBI. Ageing reduces both dopaminergic
(Kaasinen and Rinne, 2002) and noradrenergic levels
(Mann et al., 1980; Marcyniuk et al., 1986), and inﬂuences
the response to catecholaminergic drugs (Turner et al.,
2003; Castner and Goldman-Rakic, 2004; Sambataro
et al., 2012). Therefore, TBI patients would be expected
to show signiﬁcant age-dependent variations in treatment
response. There is also evidence that gender alters the
dopaminergic system, and that oestradiol levels act in com-
bination with genetic variants in the dopamine system to
affect cognitive measures in an inverted-U manner (Jacobs
and D’Esposito, 2011). Experimentally, animal models of
TBI have demonstrated gender-speciﬁc altered response to
catecholaminergic therapies, with female rats displaying
little cognitive beneﬁt but excessive motor response when
treated with doses of methylphenidate that are therapeutic
for males (Wagner et al., 2007).
Genetic variations in the catecholaminergic systems may
also inﬂuence how these systems are affected by TBI. As
discussed above, variability in COMT genotype has signiﬁ-
cant effects on dopamine status, primarily within the PFC,
which is likely to be relevant to cognitive problems follow-
ing TBI. In addition, genetic variations in the linked
ankyrin repeat and kinase domain (ANKK1) and dopamine
D2 receptor genes have been associated with differences in
cognitive recovery following TBI (Failla et al., 2015). As
recently hypothesized by Myrga et al. (2015), these innate
factors could be used to predict an individual’s baseline
location on the inverted-U framework for cognitive per-
formance. Hence, patients already lying to the left of the
inverted-U for innate or genetic reasons are likely to be
more susceptible to the hypodopaminergic effects of TBI
and also more likely to respond to dopaminergic medica-
tions. In the future, an assessment of these factors for an
individual would be usefully incorporated into treatment
decisions.
Conclusions
The cause of cognitive problems following TBI is multifac-
torial but there is good evidence that disruption to the
catecholaminergic neurotransmitter systems is an important
cause in some patients. These systems modulate many of
the cognitive functions that are impaired following TBI and
are themselves affected by TBI. Drugs affecting dopamine
and noradrenaline can enhance cognitive impairments in
some cases, but treatment response is very variable. This
variability is probably due to the heterogeneity of the dis-
ease as well as the non-linear effect of the catecholamines
on cognitive functions. Therefore, an accurate assessment
of an individual’s catecholaminergic status is likely to be
necessary to direct treatment. There are various molecular,
structural and functional imaging methods that could
achieve this but further research is required. In particular,
further mechanistic work is needed to delineate the exact
nature and cause of disruption to the catecholaminergic
systems, and the utility of these imaging techniques in pre-
dicting response to treatments also need to be established.
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